Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 264.00
Bid: 262.00
Ask: 266.00
Change: 14.00 (5.60%)
Spread: 4.00 (1.527%)
Open: 253.00
High: 270.00
Low: 263.00
Prev. Close: 250.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal

Wed, 13th Mar 2024 20:49

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

PensionBee Group PLC - UK online pension provider - Says revenue increased 35% to GBP23.8 million in 2023 from GBP17.7 million a year prior. Pretax loss narrowed to GBP10.7 million from GBP22.4 million. Adjusted loss before interest, tax, depreciation and amortisation shrunk to GBP8.2 million from GBP19.5 million. Basic loss per share dropped 53% to 4.73p from 9.97p. Assets under administration reached GBP4.35 billion at year-end, up 44% from GBP3.03 billion at the end of 2022. Chief Executive Officer Romi Savova says: "Having met our longstanding and ambitious goal of achieving adjusted Ebitda profitability across the fourth quarter of 2023, we are confident in our continued growth, underpinned by profitability...we have announced our proposed expansion into the US, the world's largest defined contribution pension market, where we see an enormous opportunity to assist many consumers in the US who also struggle to prepare adequately for retirement as they navigate a complex and confusing pensions landscape." Looking ahead, PensionBee says it is aiming to onboard 1 million invested customers, creating a revenue ambition of around GBP150 million in the long term.

----------

Faron Pharmaceuticals Ltd - Turku, Finland-based drug discovery and development company - Says its pretax loss widened to EUR30.9 million in 2023 from EUR28.7 million a year prior. The company's net assets totalled a negative EUR15.2 million at year-end, increased from a negative EUR11.5 million at the end of 2022. Says trials of its Bexmarilab cancer immunotherapy candidate made significant progress over the year. Chief Executive Officer Markku Jalkanen says: "Throughout the course of the year, we have reported highly encouraging data for bexmarilimab, showing a remarkable overall response rate in both higher-risk frontline MDS patients as well as HMA-failed MDS patients. These are highly significant findings, given the combinations of treatments these patients had previously failed on and the very limited options available for future therapy. They provide us with a path to market and only bolster our confidence in the potential of this novel immunotherapy to treat patients with aggressive hematological malignancies."

----------

Public Policy Holdings Company Inc - Washington DC-based group of advisory firms specialising in government addairs and public relations - Achieves "record financial performance and excellent strategic progress" in 2023. Revenue grew 24% to USD135.0 million from USD108.8 million. Underlying Ebitda rose 12% to USD35.1 million from USD31.2 million, in line with market expectations. Underlying net income increased 14% to USD26.5 million from USD23.3 million. Basic underlying earnings per share rose 9.7% to 23.54 cents from 21.45 cents. PPHC's annual dividend of 14.30 cents per share was 2.1% ahead of 14.00 cents a year before. All business segments achieved year-on-year growth. The company credits its successful year to several acquisitions, including MultiState Associates Inc, which "contribut[ed] healthily to group revenue and Ebitda" over 2023. PPHC continues to target an Ebitda margin of between 25% and 30%, in line with 2023's 26% margin. Chief Executive Officer Stewart Hall says: "The increasing demand for our services has enabled us to generate solid levels of organic growth and healthy expansion in total client numbers. Strategically, we are progressing well with a healthy pipeline of value accretive acquisition opportunities and the strength of our holding company model being validated by the outperformance of our two most recent acquisitions."

----------

Sovereign Metals Ltd - Graphite development company focused on projects in Malawi - In the half-year ended December 31, the company's operating loss was AUD7.0 million, narrowed from AUD8.5 million a year prior. Exploration and evaluation expenditure totalled AUD5.0 million, down from AUD5.8 million, which the company says stems from the pre-feasibility study at its Kasiya project in Malawi. Interest income grew to AUD938,402 from AUD138,366.

----------

Commonwealth Bank of Australia - Sydney-based financial services company and retail bank - Issues subordinated notes worth USD1.25 billion, due March 2034. The notes were issued pursuant to the company's USD50.00 billion senior and subordinated medium term notes program.

----------

OptiBiotix Health Ltd - life sciences company focused on tackling obesity, high cholesterol, diabetes and skincare - Signs partnership agreement with Dr Morepen Ltd, a New Delhi-based diagnostics company, for the sale of SlimBiome weight-loss products in India under the latter's brand. Chief Executive Officer Stephen O'Hara says: "Morepen brings an extensive sales team with experience of highly differentiated scientific products and countrywide access to a network of around 500,000 pharmacies across India. Based on current forecasts, the directors anticipate this agreement could contribute in the region of GBP6-7 million revenue per annum in the next four to five years."

----------

MacFarlane Group PLC - Glasgow-based packaging company - Acquires Allpack Packaging Supplies Ltd, a Bury Saint Edmunds-based packing materials business. Says the "earnings-enhancing acquisition further progresses Macfarlane's strategy to build its protective packaging business through a combination of organic and acquisitive growth". In 2023, Allpack delievered GBP3.0 million in sales alongside Ebitda and pretax profits of GBP600,000. All of Allpack's employees will join MacFarlane. MacFarland will provide a maximum consideration of GBP3.3 million, including a GBP750,000 performance-based earn-out, financed from the company's existing bank facility.

----------

Cora Gold Ltd - gold exploration company focused on Mali and Senegal - Following conversion of USD2.3 million of convertible loan notes for 82.0 million ordinary shares of no par value in the company, has issued an outstanding CLN for a total of USD13.0 million matured on March 12. The company's cash balance is now in excess of USD2.9 million. Chief Executive Officer Bert Monro says: "With strong cash reserves, we look forward to providing progress updates on our Sanankoro gold project in Mali, including submission of the application for a mining permit once the current moratorium is lifted, as well as wider exploration activities across our permits."

----------

Electric Guitar PLC - Reading-based marketing services company - Intends to request the Financial Conduct Authority to cancel the company's shares on the FCA official list and cease admission to trading on the main market of the London Stock Exchange. This is ahead of its proposed application for admission of its shares to trading on AIM. The company expects to convene a shareholder meeting to approve its acquisition of 3radical Ltd in the coming weeks.

----------

Capricorn Energy PLC - Edinburgh-based oil and gas exploration company - Securities and Exchange Board of India has ordered Vedanta Ltd to pay the company USD9.5 million within 45 days. The payment related to a non-payment of a dividend to Capricorn UK Holdings by Vedanta, a Mumbai-based mining company.

----------

Oxford BioDynamics PLC - Oxford-based biotechnology company with a portfolio of clinical tests using its EpiSwitch technology - Announces a fundraising by way of a placing to raise GBP9 million and a retail offer for up to GBP1.3 million, both with an issue price of 9p per share. The issue price represents a 21% discount to the company's closing price of 11.40p on Tuesday. The results of the placing are expects to be released on Thursday. Shares in Oxford BioDynamics closed down 11% at 10.20 pence each in London on Wednesday.

----------

Cooks Coffee Co Ltd - New Zealand-based UK-focused cafe chain - Announces its intention to undertake a placement and share purchase plan. The scheme will result in up to 5.7 million new shares in the company at an issue price of NZD0.20 per share, targeting a raise of up to NZD1.7 million, roughly GBP820,000. Cooks says that the purpose of the fundraise is to invest in improvements in the company's digital programs, including its delivery, click and collect, loyalty programs, as well as expanding its businesses in the Middle East and Europe.

----------

By Hugh Cameron, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
12 Sep 2018 13:48

Faron Pharmaceuticals Says New Clever-1 Data Shows B Cell Response

LONDON (Alliance News) - Faron Pharmaceuticals Ltd said Wednesday that new data from its cell surface receptor Clever-1 showed B cell response control and humoral antibody production.The by

Read more
6 Sep 2018 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 7 September Secure Income REITHalf Year Results Ashmore GroupFull Year Year

Read more
21 Jun 2018 16:31

DIRECTOR DEALINGS: Faron Pharmaceuticals Directors Buy Shares

LONDON (Alliance News) - Faron Pharmaceuticals Oy said on Thursday several directors purchased shares over the course of three days from Tuesday to Thursday.On Tuesday, Non-Executive Matti

Read more
14 Jun 2018 11:30

Faron Pharmaceutics Reports Inconsistent Traumakine Biomarker Results

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Thursday said preliminary biomarker data from its Traumakine phase III trial has produced inconsistent results.Faron is testing in a III

Read more
14 Jun 2018 11:00

WINNERS & LOSERS SUMMARY: Rolls Royce Flies High With Planned Job Cuts

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - up 2.6%. The jet engine maker said it will cut

Read more
24 May 2018 16:10

UK Shareholder Meetings Calendar - Next 7 Days

Friday 25 MayHochschild MiningFerrexpoKeywords Mutual (re managed 28 events 29 Stobart Life (re of

Read more
11 May 2018 08:45

Faron Says Traumakine Trial Did Not Produce Expected Results

LONDON (Alliance News) - Faron Pharmaceuticals Ltd said Friday that initial review of the Phase III trial for Traumakine drug used for the treatment of lung inflammation did not produce the seen a

Read more
8 May 2018 11:10

WINNERS & LOSERS SUMMARY: Virgin Money Gains On CYBG Takeover Offer

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - up 4.1%. The Irish drugmaker said it has agreed

Read more
8 May 2018 10:17

Faron Pharmaceuticals Shares Dive As Traumakine Fails In Latest Test

LONDON (Alliance News) - Shares in Finnish firm Faron Pharmaceuticals Oy plunged on Tuesday as the company reported "extremely disappointing" results from its flagship Traumakine shares

Read more
8 May 2018 07:01

LONDON MARKET EARLY CALL: Stocks Called Lower As Iran Fears Boost Oil

LONDON (Alliance News) - Stock prices in London are seen opening lower on Tuesday following Monday's UK bank holiday as Chinese exports recovered at a faster pace in April amid concerns the US

Read more
1 May 2018 16:15

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 2 May Direct Line Insurance GroupQ1 ResultsConvaTec GroupQ1 GroupHalf

Read more
4 Apr 2018 12:53

Tiziana Appoints Leopoldo Zambeletti As Non-Executive Director

LONDON (Alliance News) - Tiziana Life Sciences PLC, a biotechnology company developing drugs for cancer and autoimmune diseases, said Wednesday Leopoldo Zambeletti has joined

Read more
9 Feb 2017 08:20

Faron Pharmaceuticals makes solid progress with drug programmes

(ShareCast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals updated the market on Thursday, ahead of its full year 2016 audited financial results which its board said will be announced on 29 March. The AIM-traded firm said for its Traumakine project, it expects to obtain the re

Read more
31 Oct 2016 12:44

Faron Pharma granted protection for IFN-beta by Finnish patent office

(ShareCast News) - Faron Pharmaceuticals' patent application to protect the intravenous use of interferon-beta, a cytokine protein, in a novel formulation has been accepted by the Finnish patent office that enables the company to build a global proprietary position for its Traumakine drug. The claim

Read more
24 Oct 2016 08:33

Faron Begins Recruitment For Japanese Phase 3 Traumakine Trial

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.